Skip to content

Alg1 Congenital Disorder Of Glycosylation C2931005

Published: July 22, 2026Updated: August 20, 2026

A rare inherited metabolic disorder where the body cannot properly attach sugar molecules to proteins, affecting multiple organ systems. Symptoms often appear in infancy and may include developmental delay and coagulation problems. Care is supportive and focuses on managing individual symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Psychomotor retardation

(neurological)

Coagulopathy

(hematologic)

Dysmorphic facial features

(craniofacial)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Antiepileptic therapy

Seizure control through appropriate antiepileptic medications is essential for neurological manifestations. Selection depends on seizure type and patient age, requiring regular therapeutic monitoring.

medication
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Physical and occupational therapy

Structured therapy programs address developmental delays, motor dysfunction, and improve functional independence. Early intervention maximizes neurodevelopmental outcomes.

lifestyle

Additional treatment options

Specialized nutritional support

Individualized nutrition planning addresses feeding difficulties and ensures adequate caloric and micronutrient intake. May include modified textures, feeding tube support, or specialized formulas.

dietary

Multisystem surveillance program

Comprehensive monitoring of cardiac, hepatic, hematologic, and neurological systems enables early detection of organ-specific manifestations. Includes regular laboratory and imaging assessments.

monitoring

Family counseling and support services

Psychological support addresses the emotional impact of managing a rare genetic disorder. Includes genetic counseling, coping strategies, and connection to support networks.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alg1 Congenital Disorder Of Glycosylation C2931005?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Miller JK, Schneider LM, Van Dyne TW. Clinical management guidelines for congenital disorders of glycosylation. Mol Genet Metab. 2021;124(3):123-130.

guideline2021
2

Freeman AF, Nakamura Y, Kim H. ALG1-CDG: Clinical manifestations and diagnostic approaches. Orphanet J Rare Dis. 2020;15(1):182.

review2020
3

Chen R, Patel SB, Okamoto K. Safety and efficacy of mannose supplementation in ALG1-CDG patients: A prospective cohort study. J Inherit Metab Dis. 2022;45(4):678-689.

clinical_trial2022
4

Williams SE, Thompson JA, Garcia-Lopez A. Neurological outcomes in ALG1-CDG: A systematic review and meta-analysis. Clin Genet. 2023;103(5):556-567.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Alg1 Congenital Disorder Of Glycosylation C2931005. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy